It is well-established that HER2-overexpressing or triple negative breast cancer developed more local recurrence disease and distant metastases than luminal subtypes.20,24 We and others6,13 also observed that high-risk patients with higher histologic grade or more advanced tumor or nodal disease received less immediate breast reconstruction treatment than low-risk women. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.